NCT07286253 2025-12-16
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07243691 2025-11-24
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Phase NA Recruiting
NCT06490718 2025-09-08
Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery
Chinese University of Hong Kong
Phase NA Completed
NCT04099797 2025-09-04
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine
Phase 1 Recruiting
NCT06505837 2025-08-28
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Active not recruiting
NCT05894889 2025-07-23
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
Peking University
Phase 2 Active not recruiting
NCT07024030 2025-06-17
DGPR1008
The Affiliated Hospital of Qingdao University
Phase 2 Completed
NCT03238248 2024-11-04
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT04477772 2024-05-16
A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed
NCT06330337 2024-03-26
Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase 3 Recruiting
NCT06232694 2024-01-31
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT05053308 2023-08-07
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Seoul National University
Phase NA Withdrawn
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05798546 2023-04-04
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
Phase 1 Unknown